PortfoliosLab logoPortfoliosLab logo
ONC vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ONC vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BeOne Medicines Ltd (ONC) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ONC achieves a -8.17% return, which is significantly higher than NVO's -14.57% return. Over the past 10 years, ONC has outperformed NVO with an annualized return of 24.30%, while NVO has yielded a comparatively lower 6.21% annualized return.


ONC

1D
1.57%
1M
-6.10%
YTD
-8.17%
6M
-17.42%
1Y
10.84%
3Y*
7.06%
5Y*
-4.61%
10Y*
24.30%

NVO

1D
-2.14%
1M
-5.38%
YTD
-14.57%
6M
-8.62%
1Y
-38.01%
3Y*
-16.72%
5Y*
2.89%
10Y*
6.21%
*Multi-year figures are annualized to reflect compound growth (CAGR)

ONC vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ONC
BeOne Medicines Ltd
-8.17%64.48%2.41%-18.00%-18.82%4.85%55.88%18.18%43.53%221.87%
NVO
Novo Nordisk A/S
-14.57%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between ONC and NVO is 0.22, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.22

Correlation (3Y)
Calculated over the trailing 3-year period

0.15

Correlation (5Y)
Calculated over the trailing 5-year period

0.21

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Feb 4, 2016

0.22

Fundamentals

Market Cap

ONC:

$32.30B

NVO:

$186.85B

EPS

ONC:

$4.49

NVO:

$27.42

PE Ratio

ONC:

62.08

NVO:

1.53

PS Ratio

ONC:

5.55

NVO:

0.57

PB Ratio

ONC:

6.79

NVO:

0.92

Total Revenue (TTM)

ONC:

$5.74B

NVO:

$327.80B

Gross Profit (TTM)

ONC:

$5.07B

NVO:

$268.30B

EBITDA (TTM)

ONC:

$954.09M

NVO:

$181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ONC vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ONC
ONC Risk / Return Rank: 4949
Overall Rank
ONC Sharpe Ratio Rank: 5151
Sharpe Ratio Rank
ONC Sortino Ratio Rank: 4747
Sortino Ratio Rank
ONC Omega Ratio Rank: 4545
Omega Ratio Rank
ONC Calmar Ratio Rank: 5050
Calmar Ratio Rank
ONC Martin Ratio Rank: 5050
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 1414
Overall Rank
NVO Sharpe Ratio Rank: 1010
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 1313
Sortino Ratio Rank
NVO Omega Ratio Rank: 1212
Omega Ratio Rank
NVO Calmar Ratio Rank: 1515
Calmar Ratio Rank
NVO Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ONC vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BeOne Medicines Ltd (ONC) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ONCNVODifference
Sharpe ratioReturn per unit of total volatility

+1.00

Sortino ratioReturn per unit of downside risk

+1.52

Omega ratioGain probability vs. loss probability

1.08

0.88

+0.20

Calmar ratioReturn relative to maximum drawdown

0.40

-0.69

+1.09

Martin ratioReturn relative to average drawdown

0.82

-1.03

+1.85

ONC vs. NVO - Sharpe Ratio Comparison

The current ONC Sharpe Ratio is 0.26, which is higher than the NVO Sharpe Ratio of -0.74. The chart below compares the historical Sharpe Ratios of ONC and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ONCNVODifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.26

-0.74

+1.00

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.08

0.08

-0.16

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.44

0.19

+0.25

Sharpe Ratio (All Time)

Calculated using the full available price history

0.44

0.47

-0.03

Drawdowns

ONC vs. NVO - Drawdown Comparison

The maximum ONC drawdown since its inception was -69.96%, smaller than the maximum NVO drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for ONC and NVO.


Loading charts...

Drawdown Indicators


ONCNVODifference

Max Drawdown

Largest peak-to-trough decline

-69.96%

-74.70%

+4.74%

Max Drawdown (1Y)

Largest decline over 1 year

-27.23%

-55.03%

+27.80%

Max Drawdown (3Y)

Largest decline over 3 years

-42.73%

-74.70%

+31.97%

Max Drawdown (5Y)

Largest decline over 5 years

-69.96%

-74.70%

+4.74%

Max Drawdown (10Y)

Largest decline over 10 years

-69.96%

-74.70%

+4.74%

Current Drawdown

Current decline from peak

-30.79%

-69.48%

+38.69%

Average Drawdown

Average peak-to-trough decline

-29.62%

-17.76%

-11.86%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.24%

36.88%

-23.64%

Volatility

ONC vs. NVO - Volatility Comparison

BeOne Medicines Ltd (ONC) has a higher volatility of 10.72% compared to Novo Nordisk A/S (NVO) at 7.84%. This indicates that ONC's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ONCNVODifference

Volatility (1M)

Calculated over the trailing 1-month period

10.72%

7.84%

+2.88%

Volatility (6M)

Calculated over the trailing 6-month period

25.55%

37.83%

-12.28%

Volatility (1Y)

Calculated over the trailing 1-year period

41.75%

51.76%

-10.01%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

56.29%

38.21%

+18.08%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

55.79%

32.49%

+23.30%

Dividends

ONC vs. NVO - Dividend Comparison

ONC has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 4.29%.


PositionTTM20252024202320222021202020192018201720162015
NVO
Novo Nordisk A/S
4.29%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%
ONC
BeOne Medicines Ltd
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ONC vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between BeOne Medicines Ltd and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
1.51B
96.82B
(ONC) Total Revenue
(NVO) Total Revenue
Values in USD except per share items

ONC vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between BeOne Medicines Ltd and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

75.0%80.0%85.0%90.0%95.0%20222023202420252026
89.0%
86.0%
Portfolio components
ONC - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, BeOne Medicines Ltd reported a gross profit of 1.35B and revenue of 1.51B. Therefore, the gross margin over that period was 89.0%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

ONC - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, BeOne Medicines Ltd reported an operating income of 249.90M and revenue of 1.51B, resulting in an operating margin of 16.5%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

ONC - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, BeOne Medicines Ltd reported a net income of 227.36M and revenue of 1.51B, resulting in a net margin of 15.0%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.


Frequently Asked Questions


ONC and NVO have a correlation of 0.22, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ONC has higher volatility (10.72%) compared to NVO (7.84%). In terms of maximum drawdown, ONC dropped -69.96% vs NVO's -74.70%.

ONC currently has the higher Sharpe Ratio (0.26 vs -0.74), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ONC and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer